Nutraceuticals in the Prevention and Therapeutic Treatment of Cardiovascular and Cerebrovascular Disease.
| Autor: | Fleenor BS; Clinical Exercise Physiology, Human Performance Laboratory, Ball State University, Muncie, Indiana (Dr Fleenor and Mr Carlini); and Kinesiology and Applied Physiology, University of Delaware, Newark, Delaware (Dr Martens)., Carlini NA, Martens CR |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of cardiopulmonary rehabilitation and prevention [J Cardiopulm Rehabil Prev] 2023 May 01; Vol. 43 (3), pp. 162-169. Date of Electronic Publication: 2023 Jan 19. |
| DOI: | 10.1097/HCR.0000000000000773 |
| Abstrakt: | Purpose: This review overviews and highlights arterial stiffening as a key physiological process and target for the prevention and/or lowering of cardio- and cerebrovascular disease (collectively CVD) risk. Methods: We identified nutraceutical approaches from randomized controlled trials and discussed the associated mechanisms by which these compounds lower age-related arterial stiffness. Age-related CVD are the leading cause of mortality in modernized societies. Arterial dysfunction, specifically stiffening of the large elastic arteries during midlife, is a key physiological process resulting in increased CVD risk. Current pharmaceutical approaches for lowering age-related arterial stiffness have limited efficacy, thus highlighting the need to identify novel approaches for lowering arterial stiffness and thereby CVD risk. Lifestyle interventions are a historical first-line approach to prevent and/or lower the adverse arterial stiffening effects observed with aging. Nutraceutical interventions, defined as a food or part of a food providing health benefits, are a nonpharmacological, novel lifestyle approach to lower age-associated arterial stiffness. Therefore, identifying nutraceutical approaches to lower CVD risk is clinically significant. Summary: This review provides a basic, yet essential, understanding for emerging nutraceutical strategies for the prevention and therapeutic treatment of CVD. Competing Interests: The authors declare no conflicts of interest. (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|